Table 1.

Reaching the Recommended Treatment, via a Prognostic Model, between 4 Options: Placebo, Glatiramer Acetate, Dimethyl Fumarate, and Natalizumab (Hypothetical Example in Relapsing-Remitting Multiple Sclerosis)

Treatment	Placebo	Glatiramer Acetate	Dimethyl Fumarate	Natalizumab
Predicted risk to relapse within 2 y $(R_{i,j})$	75%	66%	52%	44%
Predicted risk difference versus placebo $(R{D}_{i,j})$	-	9%	23%	31%
Threshold value for treatment j ( $T_j)$		10%	10%	20%
$R{D}_{i,j}-T_j$		−1%	12%	11%
Recommended treatment via the prediction model	Dimethyl fumarate

The bold font indicates the maximum difference between the risk difference of treatment j, RDi, j, and its threshold value Tj, based on which the optimal treatment via the prediction model is recommended.